Understanding Female Libido and Hormonal Balance

The pressure campaign, “Even the Score,” was orchestrated by a pharmaceutical company with a lackluster product—flibanserin—but the vigorous support of twenty-six organizations, from the National Organization for Women and the National Council of Women’s Organizations to the Association of Reproductive Health Professionals. The pro−pink pill forces claimed that it was “sexist” that men had drugs to treat sexual dysfunction while women did not.

• Pink pills for women are dietary supplements aimed at enhancing female health.
• They often contain vitamins like B6, B12, and folic acid for overall wellness.
• Some pink pills focus on boosting libido and sexual health in women.
• Ingredients may include herbal extracts such as ginseng or damiana.
• Pink pills are marketed as aids for hormonal balance and mood improvement.
• They are available over-the-counter in health stores and online.
• Always check the ingredient list for allergens or harmful substances.
• Consult a healthcare professional before starting any supplement regimen.
• Pink pills may support skin health and reduce signs of aging.
• They are popular for promoting energy and reducing fatigue.
• Use pink pills alongside a balanced diet for optimal results.

It was high time, they argued, that the FDA level the playing field by approving flibanserin, the availability of which would provide some small restitution for decades of prioritizing “men’s sexual dysfunction…over women’s.” Pressing this demand were members of Congress, 60,000 signatories to a petition, compensated thought leaders from the academy and industry, and powerful lobbyists working on behalf of Even the Score.

i am no longer interested in masturbating

All of this activism came to a head at the FDA advisory panel hearings in June 2015, which one dissenting member described as “very high pressure” and “kind of an intimidating environment.” The intimidation worked. The advisory panel recommended approval by a margin of 18−6, and in August 2015 the FDA approved flibanserin to treat “acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.” Within two days of this triumph of genderless sexual “equity,” the owners of Sprout Pharmaceuticals, whose one possession was flibanserin, sold the company for $1 billion and a share of future profits. For many years now, pharmaceutical companies have raced to win FDA approval for a treatment for the “mental disorder” of low or absent sexual desire in women.

Age Range	Common Goals	Key Concerns	Typical Usage Frequency
18-25	Skin clarity, energy boost	Acne, fatigue	Daily or bi-daily
26-35	Hormonal regulation, beauty	PMS, skin elasticity	Daily
36-45	Anti-aging, hormonal balance	Wrinkles, menopause symptoms	Daily or as advised
46+	Support menopause health	Hot flashes, bone health	As per doctor

But contrary to what Even the Score campaigners allege, “women’s sexual dysfunction” has not been overlooked.

Product	Dosage	Quantity + Bonus	Price
Levitra Generic	20mg	30 + 4 Pills	70.59€ 67.23€	Buy
Kamagra Gold	50 mg	120 + 6 Pills	281.13€ 267.74€	Buy
Levitra Soft Tabs	20mg	270 + 10 Pills	521.78€ 496.93€	Buy
Cialis Generic	10mg	20 Pills	48.23€ 45.93€	Buy
Kamagra Gold	50 mg	360 + 6 Pills	713.95€ 679.95€	Buy
Cialis Professional	40mg	90 + 2 Pills	348.59€ 331.99€	Buy
Viagra Generic	100mg	20 Pills	45.58€ 43.41€	Buy
Levitra Professional	20mg	90 + 2 Pills	304.49€ 289.99€	Buy
Levitra Soft Tabs	20mg	180 + 10 Pills	398.14€ 379.18€	Buy
Viagra Generic	100mg	360 + 10 Pills	330.21€ 314.49€	Buy

There is a whole industry of non-pharmaceutical therapeutic interventions, techniques, and training exercises, not to mention at least one FDA-approved apparatus for treating orgasmic difficulties, the Eros-Clitoral Therapy Device. But ever since sildenafil (brand name Viagra), the impotency drug for men, came on the market in 1998, there has been a fierce industry competition to get FDA approval for a pill, a patch, or a cream for women, with a number of competitors entering and exiting the field. The experience with Viagra, widely used recreationally, suggested the potential for a blockbuster. One of the competitors was testosterone, the male hormone.

• Pink pills include ingredients like evening primrose oil.
• They aim to support breast health and tissue elasticity.
• These supplements are popular among women of all ages.
• Pink pills may help in reducing breast tenderness.
• They often contain minerals like zinc for skin health.
• Some formulations are designed for menopause transition.
• The aesthetic appeal is part of marketing strategies.
• Scientific research on pink pills is ongoing.
• User feedback varies based on individual biology.
• Always follow recommended dosage instructions.
• Pink pills are best used as part of a holistic health plan.

After some eight years of testing Viagra on women, its manufacturer, Pfizer, gave up in 2004, acknowledging that a drug that enhanced blood flow to the pelvic region after sexual stimulation might not induce women to desire sex in the first place. At the time, a professor of clinical medicine at Columbia University made a troubling suggestion: “What we need to do is find a pill for engendering the perception of intimacy.” She seemed serious. The German pharmaceutical company Boehringer Ingelheim thought it had such a pill in flibanserin. Originally tested in men and women as an antidepressant, the compound proved ineffective and was rejected by the FDA.

Sorry, this item is out of stock

But unlike most antidepressants, this one did not diminish sexual desire among the drug-trial participants; in fact, female participants scored higher than women on either a placebo or an approved antidepressant when asked “How strong is your sex drive?” Seeing an opportunity, Boehringer repurposed the drug for a different disorder. In 2010, Boehringer sought FDA approval to market flibanserin, under the brand name Girosa, to treat HSDD. The Diagnostic and Statistical Manual of Mental Disorders defined the condition at that time (it has since been changed) identically for men and women.

Find out if treatment is right for you.

Nor are they approved to treat sexual desire disorder. Flibanserin is the first and only member of that class. Although low sexual desire is allegedly a big problem for men too, medical concern has long focused largely on women. Explanations since the 1990s have been matched to the action of whatever drug was being tested to treat it: a hormone problem, for instance, in the case of testosterone. Hence, low desire is now conceived as a neurochemical imbalance.

Non-GMO, Gluten Free Supplement

Driving this home, Even the Score defines HSDD as a “persistent biological lack of desire.” It does not claim that the disorder is unique to women. Talk of a biological lack of desire suggests that there is some normal level of desire in the human body, male and female, and implies that distress might arise directly from this somatic insufficiency. In this view, the pink pill works by mechanistically resetting desire to a more normal level—which also happens to be more in keeping with what is desired—and so the distress disappears. The complex and fundamentally interpersonal nature of sexuality, the differences between men and women, the larger social context of romantic ideals and expectations, standards of comparison, social pressure, and past experience: These issues and more are not so much denied as made irrelevant. Mysteriously, biologically, men and women want, or want to want, “the same thing.” WASHINGTON/NEW YORK (Reuters) - The first drug to treat low sexual desire in women won approval from U.S.

120 Count

health regulators on Tuesday, but with a warning about potentially dangerous low blood pressure and fainting side effects, especially when taken with alcohol. The U.S. Food and Drug Administration said the pink pill, to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be available through certified and specially trained health care professionals and pharmacies due to its safety issues. Addyi, whose chemical name is flibanserin, is designed for premenopausal women whose lack of sexual desire causes distress. The condition is formally known as hypoactive sexual desire disorder, or HSDD. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity.B.

What women are saying

The pressure campaign, “Even the Score,” was orchestrated by a pharmaceutical company with a lackluster product—flibanserin—but the vigorous support of twenty-six organizations, from the National Organization for Women and the National Council of Women’s Organizations to the Association of Reproductive Health Professionals. The pro−pink pill forces claimed that it was “sexist” that men had drugs to treat sexual dysfunction while women did not. It was high time, they argued, that the FDA level the playing field by approving flibanserin, the availability of which would provide some small restitution for decades of prioritizing “men’s sexual dysfunction…over women’s.” Pressing this demand were members of Congress, 60,000 signatories to a petition, compensated thought leaders from the academy and industry, and powerful lobbyists working on behalf of Even the Score. All of this activism came to a head at the FDA advisory panel hearings in June 2015, which one dissenting member described as “very high pressure” and “kind of an intimidating environment.” The intimidation worked. The advisory panel recommended approval by a margin of 18−6, and in August 2015 the FDA approved flibanserin to treat “acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.” Within two days of this triumph of genderless sexual “equity,” the owners of Sprout Pharmaceuticals, whose one possession was flibanserin, sold the company for $1 billion and a share of future profits.

250 Capsules

For many years now, pharmaceutical companies have raced to win FDA approval for a treatment for the “mental disorder” of low or absent sexual desire in women. But contrary to what Even the Score campaigners allege, “women’s sexual dysfunction” has not been overlooked. There is a whole industry of non-pharmaceutical therapeutic interventions, techniques, and training exercises, not to mention at least one FDA-approved apparatus for treating orgasmic difficulties, the Eros-Clitoral Therapy Device. But ever since sildenafil (brand name Viagra), the impotency drug for men, came on the market in 1998, there has been a fierce industry competition to get FDA approval for a pill, a patch, or a cream for women, with a number of competitors entering and exiting the field. The experience with Viagra, widely used recreationally, suggested the potential for a blockbuster.

30,000mg

One of the competitors was testosterone, the male hormone. After some eight years of testing Viagra on women, its manufacturer, Pfizer, gave up in 2004, acknowledging that a drug that enhanced blood flow to the pelvic region after sexual stimulation might not induce women to desire sex in the first place. At the time, a professor of clinical medicine at Columbia University made a troubling suggestion: “What we need to do is find a pill for engendering the perception of intimacy.” She seemed serious. The German pharmaceutical company Boehringer Ingelheim thought it had such a pill in flibanserin. Originally tested in men and women as an antidepressant, the compound proved ineffective and was rejected by the FDA. The disturbance causes marked distress or interpersonal difficulty.” In an apparent effort to prepare the market for the launch of Girosa, Boehringer also funded an epidemiological study, conducted by researchers with ties to the company, that suggested that 10 percent of women suffered from “desire disorder” (although more than a third of those so labeled suffered from depression, with other problems also present). There were serious profits to be made. The FDA, however, found Boehringer’s data unimpressive. Two double-blind clinical trials testing flibanserin against a placebo found, in the words of the FDA, that “the treatment effect on [self-reported] desire was neither statistically significant nor clinically meaningful.” Compared with those taking a placebo, women taking the drug reported, on average, less than one additional “satisfying sexual event” per month. Nearly 15 percent of study participants taking flibanserin dropped out because of adverse side effects (compared to 7 percent of those on a placebo). An FDA committee—composed, incidentally, mainly of women—voted unanimously to reject the drug. Boehringer then sold flibanserin to Sprout, which had been formed for the sole purpose of trying again for regulatory approval. Sprout renamed the drug “Addyi,” sponsored another clinical trial, and approached the FDA in 2013. The new trial showed marginally improved results over those from the two trials conducted in 2010, achieved by shifting the primary endpoints of efficacy on a self-rating scale of questionable validity. Further, as reported in The BMJ, almost all of the named study investigators were Sprout consultants or employees. A public-relations firm helped write up the results. Even then the drug was found to be little better than a placebo. According to the FDA, when findings from the two trials in 2010 and the one in 2013 were combined, “about 10 percent more Addyi-treated patients than placebo-treated patients reported meaningful improvements” in at least one of the primary outcomes—“satisfying sexual events,” or “sexual desire,” or “distress.” More than a third of the women in the 2013 study reported side effects. With such weak results, the FDA again demurred. Sprout appealed the decision and, in February 2014, was again denied. Despite this track record, in August 2015 the FDA officially approved Addyi for HSDD, though with strong safety warnings. What it presented to the FDA were additional safety data, including a study showing a lack of next-day driving impairments and a study, which, strangely, was done almost entirely with men, showing that interaction with alcohol was responsible for many side effects. But delayed ejaculation pills the big new development was political: the Sprout-supported Even the Score campaign.

Overdose/Missed Dose

The Sprout cofounders also started spreading money to Democratic PACs, and members of Congress began lobbying the FDA. The campaign got what it wanted, but what did it get? The letters and the lobbying presupposed, solely on the basis of claims by Boehringer and Sprout, that flibanserin was a “safe and effective medical option for treatment.” The evidence, however, suggests that it is neither safe—especially if the patient does not completely abstain from alcohol and many common medications—nor effective, and that the FDA had acted with good reason in its previous disapprovals. But as important as the impact on health is the very question of sexual desire, and what is at stake in conceptualizing it as something that can be chemically regulated. The talk of gender bias and parity, couched, paradoxically, in the genderless language of “sexual dysfunction,” obscures this question.

• Pink pills are marketed as natural alternatives to hormone therapy.
• They include ingredients such as red clover or dong quai.
• Pink pills may reduce hair thinning and promote growth.
• They are sometimes used to balance menstrual cycles.
• Some formulations focus on libido and arousal.
• They are popular for enhancing feminine confidence.
• Pink pills should be used with a healthy diet and exercise.
• Always verify the authenticity before buying online.
• Suggested usage often includes daily intake.
• Proper hydration enhances supplement absorption.
• Pink pills are generally safe when used responsibly.

In its advocacy at the FDA, Even the Score had insisted that the “score” was twenty-six FDA-approved drugs for men’s dysfunction to zero for women’s. Putting all the drugs in the same register cleverly created the impression of inequity, while also implying that they were equivalent treatments for the same problem. The drugs for men—basically Viagra-type formulations (PDE5 inhibitors), vasodilators, and testosterone—are not central nervous system agents. Nor are they approved to treat sexual desire disorder. Flibanserin is the first and only member of that class.

• Pink pills may contain amino acids aiding mental clarity.
• They are sometimes used as part of female fitness supplements.
• The color pink is chosen for branding targeting women.
• Some pink supplements include ingredients for hair growth.
• They are marketed as mood boosters for emotional balance.
• Placebo effects may influence perceived benefits.
• Proper dosage instructions are essential for safety.
• Some products are combined with other health supplements.
• Pink pills are sometimes used in beauty routines.
• The market for such pills is rapidly expanding.
• Regulatory standards for pink pills vary by country.

Although low sexual desire is allegedly a big problem for men too, medical concern has long focused largely on women. Explanations since the 1990s have been matched to the action of whatever drug was being tested to treat it: a hormone problem, for instance, in the case of testosterone. Hence, low desire is now conceived as a neurochemical imbalance.

THR Newsletters

Even then the drug was found to be little better than a placebo. According to the FDA, when findings from the two trials in 2010 and the one in 2013 were combined, “about 10 percent more Addyi-treated patients than placebo-treated patients reported meaningful improvements” in at least one of the primary outcomes—“satisfying sexual events,” or “sexual desire,” or “distress.” More than a third of the women in the 2013 study reported side effects. With such weak results, the FDA again demurred. Sprout appealed the decision and, in February 2014, was again denied. Despite this track record, in August 2015 the FDA officially approved Addyi for HSDD, though with strong safety warnings.

by Horbaach $12.99 Was $15.59

What it presented to the FDA were additional safety data, including a study showing a lack of next-day driving impairments and a study, which, strangely, was done almost entirely with men, showing that interaction with alcohol was responsible for many side effects. But delayed ejaculation pills the big new development was political: the Sprout-supported Even the Score campaign. The Sprout cofounders also started spreading money to Democratic PACs, and members of Congress began lobbying the FDA. The campaign got what it wanted, but what did it get? The letters and the lobbying presupposed, solely on the basis of claims by Boehringer and Sprout, that flibanserin was a “safe and effective medical option for treatment.” The evidence, however, suggests that it is neither safe—especially if the patient does not completely abstain from alcohol and many common medications—nor effective, and that the FDA had acted with good reason in its previous disapprovals.

Non-GMO

But as important as the impact on health is the very question of sexual desire, and what is at stake in conceptualizing it as something that can be chemically regulated. The talk of gender bias and parity, couched, paradoxically, in the genderless language of “sexual dysfunction,” obscures this question. In its advocacy at the FDA, Even the Score had insisted that the “score” was twenty-six FDA-approved drugs for men’s dysfunction to zero for women’s. Putting all the drugs in the same register cleverly created the impression of inequity, while also implying that they were equivalent treatments for the same problem. The drugs for men—basically Viagra-type formulations (PDE5 inhibitors), vasodilators, and testosterone—are not central nervous system agents. Driving this home, Even the Score defines HSDD as a “persistent biological lack of desire.” It does not claim that the disorder is unique to women. Talk of a biological lack of desire suggests that there is some normal level of desire in the human body, male and female, and implies that distress might arise directly from this somatic insufficiency. In this view, the pink pill works by mechanistically resetting desire to a more normal level—which also happens to be more in keeping with what is desired—and so the distress disappears. The complex and fundamentally interpersonal nature of sexuality, the differences between men and women, the larger social context of romantic ideals and expectations, standards of comparison, social pressure, and past experience: These issues and more are not so much denied as made irrelevant. Mysteriously, biologically, men and women want, or want to want, “the same thing.” WASHINGTON/NEW YORK (Reuters) - The first drug to treat low sexual desire in women won approval from U.S. health regulators on Tuesday, but with a warning about potentially dangerous low blood pressure and fainting side effects, especially when taken with alcohol. The U.S. Food and Drug Administration said the pink pill, to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be available through certified and specially trained health care professionals and pharmacies due to its safety issues.

What is the Pink Sex Pill For Women?

But unlike most antidepressants, this one did not diminish sexual desire among the drug-trial participants; in fact, female participants scored higher than women on either a placebo or an approved antidepressant when asked “How strong is your sex drive?” Seeing an opportunity, Boehringer repurposed the drug for a different disorder. In 2010, Boehringer sought FDA approval to market flibanserin, under the brand name Girosa, to treat HSDD. The Diagnostic and Statistical Manual of Mental Disorders defined the condition at that time (it has since been changed) identically for men and women. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity.B. The disturbance causes marked distress or interpersonal difficulty.” In an apparent effort to prepare the market for the launch of Girosa, Boehringer also funded an epidemiological study, conducted by researchers with ties to the company, that suggested that 10 percent of women suffered from “desire disorder” (although more than a third of those so labeled suffered from depression, with other problems also present).

120 Capsules

There were serious profits to be made. The FDA, however, found Boehringer’s data unimpressive. Two double-blind clinical trials testing flibanserin against a placebo found, in the words of the FDA, that “the treatment effect on [self-reported] desire was neither statistically significant nor clinically meaningful.” Compared with those taking a placebo, women taking the drug reported, on average, less than one additional “satisfying sexual event” per month. Nearly 15 percent of study participants taking flibanserin dropped out because of adverse side effects (compared to 7 percent of those on a placebo). An FDA committee—composed, incidentally, mainly of women—voted unanimously to reject the drug.

IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:

Boehringer then sold flibanserin to Sprout, which had been formed for the sole purpose of trying again for regulatory approval. Sprout renamed the drug “Addyi,” sponsored another clinical trial, and approached the FDA in 2013. The new trial showed marginally improved results over those from the two trials conducted in 2010, achieved by shifting the primary endpoints of efficacy on a self-rating scale of questionable validity. Further, as reported in The BMJ, almost all of the named study investigators were Sprout consultants or employees. A public-relations firm helped write up the results. Addyi, whose chemical name is flibanserin, is designed for premenopausal women whose lack of sexual desire causes distress. The condition is formally known as hypoactive sexual desire disorder, or HSDD.